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Abstract
PfEMP1 proteins comprise a family of variant antigens that appear on the surface of P. falciparum-infected erythrocytes and
bind to multiple host receptors. Using a mammalian expression system and BioPlex technology, we developed an array of
24 protein constructs representing 38 PfEMP1 domains for high throughput analyses of receptor binding as well as total and
functional antibody responses. We analyzed the reactivity of 561 plasma samples from 378 young Tanzanian children
followed up to maximum 192 weeks of life in a longitudinal birth cohort. Surprisingly, reactivity to the DBL5 domain of
VAR2CSA, a pregnancy malaria vaccine candidate, was most common, and the prevalence of reactivity was stable
throughout early childhood. Reactivity to all other PfEMP1 constructs increased with age. Antibodies to the
DBL2bC2PF11_0521 domain, measured as plasma reactivity or plasma inhibition of ICAM1 binding, predicted reduced risk
of hospitalization for severe or moderately severe malaria. These data suggest a role for VAR2CSA in childhood malaria and
implicate DBL2bC2PF11_0521 in protective immunity.
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Introduction
Severe malaria syndromes caused by Plasmodium falciparum kill
over 1 million African children each year. P. falciparum-infected
erythrocytes (IE) adhere to host endothelium and to red blood
cells, allowing IE to sequester in deep vascular beds of various
organs [1–5]. Sequestration may be related to severe complica-
tions, like cerebral malaria, placental malaria, respiratory distress,
and severe anemia [6–10]. Parasite adhesion and sequestration are
thought to be mediated by the PfEMP1 family (,60 members per
genome) of clonally variant surface-expressed erythrocyte mem-
brane proteins [11–13].
The role of specific PfEMP1 proteins in severe malaria
syndromes remains unclear. A single member of the PfEMP1
family, VAR2CSA, is upregulated by IE that sequester in the
placenta during pregnancy malaria (PM) (reviewed in [14]). PM
risk decreases after one or two pregnancies as women acquire anti-
adhesion antibodies to placental parasites [15] and greater plasma
reactivity to VAR2CSA [16,17]. By comparison, severe syndromes
(cerebral malaria, respiratory distress, and severe anemia) may
occur only once or twice in exposed children [18,19], and only a
small number (1–2%) of parasitemia episodes progress to severe
malaria [20]. This epidemiology supports a model in which severe
malaria is caused by a limited number of parasite variants, possibly
expressing particular PfEMP1 alleles that determine specific
parasite adhesion, similar to pregnancy malaria. The rapid
acquisition of resistance to severe malaria [19,21] also implies
that the targets of the protective immune response have conserved
features.
Using a mammalian expression system and BioPlex technology,
we developed a high throughput system to study arrays of correctly
folded PfEMP1 domains for analyses of receptor binding, and for
measurements of total (plasma reactivity) and functional (inhibition
of receptor binding) antibody levels [22]. In previous work, using a
small set of sera, we found that antibodies that inhibit binding of
ICAM1 to DBL2bC2PF11_0521 are common in adults and rare in
infants. In the current work we expand the panel of domains to
study the development of anti-PfEMP1 immunity in young
children. PfEMP1 proteins belonging to group A (previously
implicated in severe malaria [23]), groups B, B/C, and C (that
typically bind the glycoprotein CD36), and VAR2CSA (previously
implicated in pregnancy malaria [16,17]) were included in the
array as single or tandem domains. In total, we assayed 561
plasma samples from 378 young children followed up to age 192
weeks in longitudinal birth cohort studies in Tanzania [24] for
reactivity to 24 protein constructs representing 38 PfEMP1
domains. We observed widespread and persistent recognition of
the pregnancy malaria antigen VAR2CSA by plasma of young
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e31011children. In addition, antibodies to an ICAM1-binding PfEMP1
domain, DBL2bC2PF11_0521, predicted a reduced risk of hospi-
talization for severe or moderately severe malaria.
Results and Discussion
Multi-domain NTS-DBL1-CIDR1 constructs bind CD36
In their native state, proteins exist in a folded form, which can
create conformationally dependent epitopes and also mask cryptic
epitopes. For this reason, correctly folded recombinant proteins
may have lower seroreactivity than unfolded proteins [17,25],
which could be explained by cryptic epitopes. Consequently, the
use of correctly folded proteins for seroreactivity studies might
yield clearer associations with clinical outcomes by displaying
relevant epitopes, but not irrelevant cryptic epitopes against which
antibodies cannot bind in the native protein.
We previously expressed all DBLbC2 domains encoded in the
genome of parasite clone 3D7, and surveyed their binding
properties [22]. Because CIDR domains always follow DBL
domains, DBL-CIDR tandems may organize structural-functional
units within PfEMP1 proteins. Therefore, we prepared 14
multidomain constructs containing DBL-CIDR tandems
(Figure 1), including 12 comprised of N-terminal segment
(NTS)-DBL1-CIDR1 domains that constitute the semi-conserved
PfEMP1 N-terminal head structure [26]. These head structures, as
well as 3 single CIDR1 domains and 2 NTS-DBL1 constructs,
were prepared and tested for binding to CD36, as we previously
described for DBLbC2::ICAM1 interactions [22].
The CD36 binding results obtained with multidomain con-
structs that contain CIDR1 (Table 1) correspond qualitatively to
results reported earlier for single CIDR1 domains in a different
system [26]. Based on dilution curves, CIDR1-containing
constructs of PFD0995c, PFI0005w, PFC0005w, PFD0005w,
and PFF1595 bind CD36 with higher affinity than other variants,
and PF08_0106 binds with very high affinity (Table 1). As
expected [26], individual DBL1 domains (n=2) fail to bind CD36.
Thus, the domain boundaries and expression platform allow these
complex multidomain polypeptides to correctly fold into function-
al units.
In an earlier study, seroreactivity in African children was
acquired most rapidly against group A or A/B DBL1 domains, but
conversely was acquired most rapidly against group B, B/C, or C
CIDR1 domains [27]. This inconsistency has been attributed to
higher cross-reactivity against CIDR domains versus DBL
domains [28]. However only two CIDR1 domains from group B
have been tested and showed minimal cross-reactivity with group
A domains [28], and therefore more data are needed to resolve
this issue. The DBL-CIDR tandem constructs included in the
present study avoid any domain-specific bias in analyses of the
plasma reactivity of PfEMP1 head structures, and may therefore
be superior targets for seroreactivity studies.
Plasma reactivity against VAR2CSA PfEMP1 protein is
common in infants
Eleven out of 24 domain constructs were recognized by .10%
of serum samples from children above 2 years of age (Figure 1, and
Figure 2). These included 5 out of 9 PfEMP1 Group A constructs,
5 out of 13 domains from groups B, B/C, and C, and 1 out of the
2 VAR2CSA constructs (based on the proposed var gene
classification [29]). At age 76 weeks, antibody prevalence is
highest against VAR2CSA DBL5 and group A domains (Figure S1
A and B), while at later ages the prevalence of reactivity to groups
Figure 1. PfEMP1 domains tested for IgG reactivity using Tanzanian children’s plasma. PfEMP1 domain constructs studied in this work are
indicated by boxes. Shaded boxes indicate constructs recognized by $10% of children. Var gene groups according to (25) and total numbers of
PfEMP1 genes from parasite clone 3D7 genome in these groups are shown on the left.
doi:10.1371/journal.pone.0031011.g001
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Group Gene Domain Binding (AU±SD) to CD36 (mg/ml)
5 1 0.25
A PF08_0141 CIDR1c 00 0
A PF11_0008 NTS-DBL1a1 -CIDR1c*0 0 0
A PFD0020c NTS-DBL1a1-CIDR1a1* 0 0 0
A PFI1820w NTS-DBL1a1* 0 0 0
B PF08_0142 NTS-DBL1a-CIDR1a 22556268 198643 6 625
B PFA0765c NTS-DBL1a-CIDR1a 25056119 319658 5 626
B PFD0005w NTS-DBL1a-CIDR1a 2442664 5436117 14969
B PFI0005w NTS-DBL1a-CIDR1a 25446309 17276890 0
B PFB1055c NTS-DBL1a-CIDR1a 27326206 0 0
B PFC0005w NTS-DBL1a-CIDR1a 2740681 13386734 NT
B PFF1595c NTS-DBL1a-CIDR1a 27806230 9216190 NT
B PFI1830c NTS-DBL1a-CIDR1a 27756272 0 0
B/C PF08_0106 NTS-DBL1a 00 0
B/C PF08_0106 CIDR1a 1396167 119306228 6594664
B/C MAL7P1.50 NTS-DBL1a-CIDR1a NT 23276464 NT
C PFD0995c NTS-DBL1a-CIDR1a 24906115 17406939 339635
C PFD0995c CIDR1a* 34566682 27176653 NT
*Domains cloned into pAdEx, other domains cloned into pHisAdEx.
Abbreviations: AU, Arbitrary Units; SD, Standard Deviation; NT, Not Tested.
doi:10.1371/journal.pone.0031011.t001
Figure 2. Prevalence of plasma IgG reactivity to individual PfEMP1 domains, stratified by age. Bars indicate the prevalence of plasma IgG
reactivity among Tanzanian children of different ages to the indicated PfEMP1 constructs. PfEMP1 classification: V2 - VAR2CSA, A - group A, B - group
B, C - group C, B/C - group B/C (according to [29]). As indicated in Figure 1 and Table 1, DBL1-containing constructs also contain N-terminal segment
(NTS), but NTS is not included in the construct names.
doi:10.1371/journal.pone.0031011.g002
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expression has been associated with severe malaria in some studies
[23,30–32], and our data are consistent with the hypothesis that
parasites expressing group A PfEMP1 proteins prevail in the
youngest children [27] and this might contribute to severe malaria.
Alternatively, the pattern of plasma reactivity might also be due to
greater immunogenicity or higher sequence conservation of Group
A versus other var genes.
Antibodies to specific non-Group A PfEMP1 proteins that bind
avidly to CD36 (for example, PFD0995c, PFF1595c, PF08_0106,
Table 1) arose as quickly as those to Group A proteins. Similarly,
DBL2bC2PF11_0521, which binds strongly to ICAM1, was the
second most commonly recognized PfEMP1 domain after
VAR2CSA. In general, antibodies against ICAM1-binding domain
dominate at early ages, while antibodies against CD36-binding
domains increase at later ages (Figure S1 A and B). These data
support the notion that parasites expressing highly adhesive
PfEMP1 proteins may have a growth advantage and cause disease
in non-immune young children [27], but quickly induce specific
antibodiesthat controltheseparasitesand reducefuture disease risk.
If so, a fuller understanding of PfEMP1 binding properties will be
critical to develop preventive or therapeutic interventions, and can
be facilitated by our high throughput assay for PfEMP1 domains.
The prevalence of reactivity increased with age to all PfEMP1
proteins recognized by more than 5% of children except
VAR2CSA. The DBL5 domain of VAR2CSA was the best-
recognized antigen, and the prevalence of reactivity to this domain
was stable throughout early life (Figure 2). The DBL1 domain of
VAR2CSA was recognized less frequently than the DBL5 domain.
A similar phenomenon has been observed for other PfEMP1
proteins: 55% of Tanzanian children recognize the MAL6P1.4
DBL5 domain versus only 1% that recognize the MAL6P1.4
DBL3 domain [27]. These differences have been ascribed to rare
combinations of the discordant domains within one protein but
might also be due to differences in immunogenicity, surface
exposure, or sequence variability of the domains within the same
protein. The DBL4 domain in VAR2CSA PfEMP1 protein, a
main target of pregnancy malaria vaccine [16,17,33], clearly
demonstrates discordant induction of antibody. Plasma from
multigravid women infrequently react to this domain (26%
responders; zero median reactivity) compared to VAR2CSA
DBL5 and DBL3 domains (82% responders to each and
significant positive median reactivity) [17], even though these 3
domains are shared by all VAR2CSA alleles sequenced to date.
The magnitude of the immune response against DBL5 ranged
from 0 to 6674 AU among children (Figure S2A), with a
maximum comparable to that of pooled plasma of African
multigravidae at 11093 AU. Despite the putative role of
VAR2CSA in PM, more than a third of children at any age
demonstrated reactivity to this domain (Figure 2), and more than
half of children had at least one of their samples react to it (Figure
S2B). Pregnancy malaria, measured at the time of delivery for each
mother by the presence of parasites in the placenta [24], did not
predict subsequent plasma reactivity to VAR2CSA in these
children (p=0.43, Fisher’s exact test) or correlate with anti-
DBL5 IgG levels (Spearman r=0.078, p=0.07).
The higher conservation of VAR2CSA sequence compared to
other PfEMP1 may contribute to the greater frequency of
recognition, but the sustained reactivity suggests that exposure to
VAR2CSA-expressing parasites is probably common throughout
early childhood. This possibility is also supported by our earlier
mass-spectrometry analyses that detected VAR2CSA peptides in 4
out of 24 (17%) children’s parasites [34], despite the relatively low
sensitivity of mass-spectrometry to identify variant proteins.
Exposure to VAR2CSA during childhood apparently does not lead
to protection against pregnancy malaria in adult women, who are
highly susceptible to malaria at the time of their first pregnancies.
The frequency of plasma reactivity to VAR2CSA DBL5
among children is similar to that among adult males in our East
African cohort [17] and in Ghana [16], and among primigravid
w o m e ni nA f r i c a[ 1 7 ] .T h ep r e v a l e n c eo fp l a s m ar e a c t i v i t yt o
CSA-binding parasites among adult males living in Kenya and in
Papua New Guinea [35] is also comparable (35–50% responders,
depending on strain). Moreover, the same study [35] reports that
at least 13% of children recognize CSA-binding CS2 parasites.
Although the level and prevalence of reactivity to VAR2CSA is
significantly higher in pregnant multigravid women [16,17], the
widespread reactivity in plasma from children, primigravidae,
a n da d u l tm a l e se m p h a s i z e so u ri n c o m p l e t eu n d e r s t a n d i n go ft h e
protective immune response during PM. Possibly, VAR2CSA in
children’s parasites elicits different specificities than VAR2CSA
in maternal parasites, and this might result in different
proportions of non-functional and functional antibodies. For
example, VAR2CSA may form complexes with different
proteins, or appear on the surface at different densities, leading
to different conformations or epitopes seen by the immune
system. Studies by others [36] have shown that trafficking of
PfEMP1 to the host cell surface is inefficient, with abundant
intracellular PfEMP1 protein whose conformation and immu-
nogenicity may differ from that of surface-displayed PfEMP1.
This emphasizes the importance of studying functional immune
responses, such as those that inhibit adhesion of IE surface
proteins to host receptors [22].
Anti-PfEMP1 domain plasma reactivity is dynamic
At the population level, the number of reactive PfEMP1
domains (Spearman correlation coefficient r=0.12, P=0.0058)
and the sum of anti-PfEMP1 IgG reactivities (r=0.12, P=0.0033)
positively correlate with the number of preceding parasitemia
episodes (Figure S3). The relatively low degree of correlation may
be due to the incomplete repertoire of PfEMP1 domains included
in this study, and an expanded set of domains might strengthen the
relationship. Plasma reactivity to individual PfEMP1 domains
waxes and wanes with time in individual children (Figure 3). An
increase in IgG reactivity did not always correspond to a preceding
parasitemia event, even though blood smears were examined every
2–4 weeks in these children. We cannot exclude the possibility that
asymptomatic parasitemia episodes occurred between monthly or
bi-weekly blood smears, and may have affected plasma reactivity.
IgG to DBL2bC2PF11_0521 domain predicts reduced risk of
malaria hospitalizations
Infants rarely develop functional IgG [22] or plasma reactivity
[22,27] to PfEMP1 domains. In our cohort, the prevalence of
reactivity increases from age 76 weeks on, and in parallel the
proportion of children subsequently experiencing severe or
moderately severe malaria declined sharply in the 1–2 year age
window (Duffy et al., manuscript in preparation; Figure S4). For
this reason, we examined the effect of antibody measured at 76
weeks of age on subsequent risk of disease. We focused our
detailed analysis on the 2 domains (DBL2C2PF11_0521 and
VAR2CSA DBL5) that were recognized most commonly. In this
cohort, eighteen children were hospitalized after age 76 weeks with
severe or moderately severe malaria, and these included children
who suffered severe anemia (n=1), respiratory distress (n=7),
prostration (n=4), convulsions (n=2), hyperpyrexia (n=9), or
hypoglycemia (n=1). Hyperparasitemia without other features of
Immune Responses to PfEMP1 Proteins in Children
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severe malaria.
We considered two measures of plasma IgG: plasma reactivity by
ELISA, and functional antibody measured as the ability of children’s
plasma to inhibit ICAM1 binding to the DBL2C2PF11_0521 domain
[22]. The amounts of total and functional IgG for the entire set of
samples correlate modestly (Spearman r=0.19, p=0.0054), sug-
gesting that neither assay is fully sensitive for detecting antibody
responses. In contrast, the correlation between these measure-
ments in samples from immune adults [22] is significantly stronger
(r=0.61, p=0.0001). None of the children found to have
DBL2C2PF11_0521-reactive IgG, and none of the children found
to have functional antibody by binding-inhibition assay, subse-
quently suffered severe or moderately severe malaria. Because
both assays have incomplete sensitivity, and because plasma IgG
reactivity and inhibition of ICAM1 binding represent two facets
of the specific anti-domain immune response that can contribute
to protection, we analyzed whether responses detected by either
assay would predict reduced risk of disease. Children with
antibody measured in either format demonstrated a reduced risk
of Severe/Moderately severe malaria hospitalizations (p=0.048,
Fisher’s exact test; Table 2).
Potential confounding factors did not explain the relationship
between plasma IgG and malaria hospitalization risk. We analyzed
the following factors for confounding effects: 1) time from the most
recent parasitemia (i.e., confounding due to acute antibody
response); 2) duration of follow-up (i.e., confounding due to
differential observation time); 3) number of previous parasitemia
episodes (i.e., confounding due to cumulative exposure). Time
from the most recent parasitemia (p=0.36), duration of follow-up
(p=0.76), and the number of previous parasitemia episodes
(p=0.68) did not differ significantly (Mann-Whitney test) between
children with versus those without DBL2C2PF11_0521 specific
antibodies measured in one or the other assay (Figure S5). Further,
IgG directed against VAR2CSA DBL5 (p=0.62) or any domain
other than DBL2C2PF11_0521, was not associated with protection
against severe or moderately severe malaria hospitalizations
(Figure S6), suggesting the relationship to protection is specific to
the DBL2C2PF11_0521 response.
In an earlier study, IgG reactivity against the PF11_0008
CIDR2 domain was associated with protection against clinical
malaria among children 4–9 years of age, but not among younger
children, and plasma reactivity to the DBL1 and DBL2 domains of
the same protein were not related to risk. [37]. In our work, we
detected antibodies to DBL1-CIDR1 and DBL2 constructs from
this gene in children below 4 years of age, and as in the previous
study did not observe an association with protection against
parasitemia or against severe/moderately severe malaria. In
another study [38], children with IgG reactivity to VAR4 CIDR1
domain (PFD1235w gene) were less likely to have anemia (defined
as hemoglobin ,11 g/dl). We did not test this domain in our study.
Seroreactivity studies using variant antigens are limited to
some extent because it is not possible to represent the full array of
naturally occurring sequence variants. Nevertheless, our present
and previous results [22] as well as results of others [27,37,38]
suggest that meaningful conclusions are obtained despite this
limitation, possibly due to sufficient conservation/cross-reactivity
of specific epitopes within the variant antigens. For example, the
frequent recognition of DBL2bC2PF11_0521 domain by children
older than 2.5 years of age (Figure 2 and Figure S1) and by adults
[22] suggests substantial conservation of its epitopes among field
isolates. Immunity against severe malaria may be acquired
quickly in early childhood, possibly after only 1 or 2 infections
[19]. In areas of high stable transmission, severe malaria
incidence declines rapidly after 1.5 years of age [18,19], and
constitutes a small percentage of malaria cases. At our study site,
malaria transmission is intense [24], and severe malaria
hospitalizations constitute ,2% of parasitemia events in children
with a median follow up to age 156 weeks. Many children in
endemic areas never suffer severe malaria despite multiple
infectious bites, prompting speculation that they develop
immunity against severe malaria parasites while protected by
maternal antibodies in early infancy [19]. Even in areas of lower
transmission (,1 clinical attack per year), immunity against
severe malaria is largely established by the age of five years [39].
Table 2. Number of children hospitalized with subsequent
severe or moderately severe malaria, stratified by Positive
plasma reactivity (IgG.0o rB I .0) against DBL2bC2PF11_0521
domain measured at 76 weeks of age.
Subsequent severe or
moderately severe malaria
YES NO
Positive Plasma Reactivity 03 8 3 8
No Plasma Reactivity 18 166 184
18 204 222
Fisher’s Exact Text: p=0.048, OR=0.117 [95% CI=0.007 to 1.98].
Please, note that the P value computed from Fisher’s test is exactly correct.
However, the confidence intervals for the Odds ratio (OR) are computed by
methods that are only approximately correct. Because one cell contains ‘‘0’’, a
value of 0.5 was automatically added to each cell for calculation of OR
(GraphPad Prizm software). Therefore, the confidence interval does not quite
agree with the P value.
doi:10.1371/journal.pone.0031011.t002
Figure 3. Plasma IgG reactivity to PfEMP1 domains is dynamic
over time in individual children. The two panels portray two
children as representative examples who experience increases and
decreases in plasma reactivity over time against two commonly
recognized PfEMP1 domains.
doi:10.1371/journal.pone.0031011.g003
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diverse or their diversity is significantly restricted [19], and that
recognition of these parasites and their surface antigens is
acquired relatively rapidly.
Our results with 561 plasma samples and 38 PfEMP1 domains
find that antibodies against an ICAM1-binding DBL2bC2PF11_0521
domain predict resistance to severe/moderately severe malaria
hospitalization. This domain can bind host receptor ICAM1 with
high affinity, similar to the affinity of anti-ICAM1 My-13
monoclonal antibody [22]. Parasite-ICAM1 interactions have been
implicatedinthepathogenesisofcerebralmalaria[8,9],althoughthe
evidence for this hypothesis is inconclusive. A larger sample size is
needed to assess whether cerebral disease risk is specifically
associated with antibodies against the DBL2bC2PF11_0521 domain,
and to confirm the association to protection against severe/
moderatelyseveremalaria hospitalizations.Interestingly,the DBL1a
domain encoded by PF11_0521 gene belongs to Cys2 type [40]
whose transcription has been associated with severe malaria [41].
In future studies, we will expand our sample size, as well as the
number of PfEMP1 domains under study, to identify the range of
domains and binding interactions related to protection. Our
current data encourage us to further investigate the role of
DBL2bC2PF11_0521 domain in severe malaria pathogenesis and
immunity.
Materials and Methods
Ethics Statement
Human plasma samples used in these studies were collected
from East African donors under protocols approved by relevant
ethical review committees. Study participants provided written
informed consent before donating samples. Mothers gave a written
consent for themselves and their children. Ethical clearance was
obtained from Institutional Review Boards of Seattle Biomedical
Research Institute and the National Medical Research Coordi-
nating Committee in Tanzania.
Human plasma samples
Plasma samples were drawn from donors that included adult
males from Kenya [42,43] and children from Tanzania [24].
Malaria is endemic in both these regions. Plasma from 5 randomly
selected non-immune donors in the US were separated from whole
blood obtained from commercial sources (Valley Biomedical) and
used in a pool as a negative control [22]. We tested 561 plasma
samples from children (n=378) collected at 76 (n=222), 100
(n=162), 124 (n=130), and 148 (n=47) weeks of life. Children
were observed up to 192 weeks of life (median for the last visit is
136, 148.5, 168, and 184 weeks for the groups of 76, 100, 124, and
148 week tested children, respectively).
Hospitalizations for severe and moderately severe
malaria
Severe malaria was defined by WHO criteria as parasitemia
together with one or more of the following: respiratory distress
(respiratory rate $40 with physical signs of distress); two or more
observed convulsions in the past 24 hours; glucose ,2.2 mmol/L;
prostration; hemoglobin ,5.0 g/dL. Moderately severe malaria
was defined as parasitemia with symptoms that did not meet
WHO criteria for severe malaria but that met one or more of the
following criteria: a respiratory rate $40; observed convulsions in
the past 24 hours; hemoglobin ,6.0 g/dL; temperature $40uC.
Children with these presentations were commonly hospitalized for
parenteral therapy [19,44].
PfEMP1 domain array construction
Construct composition and corresponding PCR primers for 26
PfEMP1 constructs encompassing 39 DBL and CIDR domains
are shown in Table S1. 3D7 genomic DNA was used for PCR
amplification of PfEMP1 domain constructs. PfEMP1 domain
cloning into pAdEx and pHisAdEx vectors, expression in COS7
cells, and single step purification/BioPlex bead immobilization
were performed as described earlier [22]. The amount of
immobilized recombinant protein was tested by anti-GFP
antibody and was similar for all tested constructs (data not
shown). Twenty four constructs (38 domains) were used for
seroepidemiology studies (Figure 1) and 17 constructs for CD36
binding studies (Table 1).
CD36 binding activity of N-terminal head structures
Binding of CD36 at increasing concentrations to various N-
terminal head structures (Table 1) was measured as we previously
described for DBLbC2::ICAM1 interactions [22]. Briefly, mix-
tures of domains immobilized on different bead regions (Bio-Rad)
were placed into wells of HTS 96-well plates (Whatmann) in
duplicates. After incubation with different concentrations (5–
0.25 mg/ml) of CD36-human Fc receptor (R&D Systems,
Minneapolis) beads were washed and bound CD36 was detected
by anti-human IgG coupled to phycoerythrin (1:250 dilution,
Jackson ImmunoResearch). Binding of CD36 to AdEx and
HisAdEx constructs without inserts [22] was used as negative
control in each assay. Negative control reactivity plus 2 standard
deviations was subtracted from the CD36 reactivity of each
PfEMP1 domain cloned into the same vector. The resulting CD36
binding activities are presented in Table 1. Binding activities of the
same domains cloned into pAdEx or pHisAdEx vector were
similar. Reduction of CD36 by dithiothreitol (DTT) abrogates its
binding to corresponding constructs (data not shown).
IgG reactivity of children’s plasma samples against
PfEMP1 constructs
This reactivity was measured as previously described [17,22]
using a BioPlex fluorometer, and the fluorescence values obtained
for detection of bound IgG was described as arbitrary units (AU)
in our study. The secondary antibody for this assay (Jackson
Laboratory, F(ab9)2 Fragment Donkey Anti-Human IgG (H+L)
(min X Bov, Ck, Gt, GP, Sy Hms, Hrs, Ms, Rb, Rat, Shp Sr
Prot)), does not recognize human IgM (see below and Figure S7)
that may bind non-specifically to VAR2CSA DBL5 [45]. Final
reactivity of each construct was determined by subtracting the
mean plus 2 standard deviations of background reactivity from
the measured fluorescence values; background reactivity was
defined as the highest of either 1) reactivity to the control
constructs (AdEx or HisAdEx) with the same serum, or 2) mean
reactivity of pooled non-immune plasma measured in all assays
[17,22].
Reactivity of anti-human IgG with human IgG and human
IgM
To confirm by standard ELISA method that anti-human IgG
does not recognize human IgM we incubated 0.1 mg of human
IgG and IgM in carbonate/bicarbonate buffer in duplicates using
96-well plates. After overnight incubation at 4uC, washing, and
blocking in 4% milk wells were probed with various dilutions of
FITC-conjugated anti-human IgG (see above). After washing,
fluorescence (in arbitrary units, AU) was measured using
Fluoroscan Ascent FL fluorometer/luminometer (ThermoLab
systems). Results are shown in Figure S7.
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by human plasma
These measurements (including controls) were performed as
described earlier [22]. Binding inhibition (BI) was measured
relative to binding buffer. BI with non-immune plasma (defined as
0% inhibition) had standard deviation (SD) of 12.5% (16 replicate
samples on 8 different HTS 96-well plates), therefore children’s
plasma with BI above the level of 2 SD (25%) was considered as
inhibitory. Pooled immune adult male serum [22] inhibited
ICAM1 binding by 9563% in these experiments.
Statistical analyses
Analyses of proportions (contingency tables), correlation, and
Mann-Whitney tests were performed using GraphPad Prizm
software (version 4.03, La Jolla, CA). Multiple regression analyses
were performed using StatView for Windows (version 5.0.1, SAS
Institute Inc.)
Supporting Information
Figure S1 A. Age-dependent prevalence of plasma reactivity to
PfEMP1 domains ordered by decreasing reactivity measured at
week 76 of life. Note that all constructs with DBL1 domain also
contain NTS domain but it is not included in the names of
constructs in this Figure. B. Percent of children responding to any
construct in each particular PfEMP1 group, stratified by age. The
total number in each age group exceeds 100% because individual
children may respond to more than one antigen.
(PPT)
Figure S2 A. IgG reactivity of VAR2CSA DBL5 with plasma
from children of different age after subtraction of background
reactivity(meanplus2SDthreshold). AU,arbitraryunits. Reactivity
of pooled multigravida plasma (positive control) was 11093 AU.
Highest reactivity of child plasma was 6674. Red lines indicate
mean values (all median values equal to zero). Pink and blue lines
indicate 2 SDand 4 SD thresholdused foranalysisinFigure S2B. B.
Percent of children with positive IgG reactivity (detected at any age
of 76 through 148 weeks for each child) at various levels of
background reactivity threshold. The threshold level of 2SD used
for calculations of seroreactivity in this work is underlined.
(PPT)
Figure S3 Number of reactive PfEMP1 domains (A) and the
sum of anti-PfEMP1 IgG reactivities (B) positively correlate with
the number of preceding parasitemia episode. Corresponding
Spearman correlation coefficients (r) and P-values are indicated.
Blue line demonstrates linear regression.
(PPT)
Figure S4 Opposite trends in the percentage of children with
subsequent hospitalizations for severe/moderately severe malaria (A)
vs. percentage of children with total or functional seroreactivity against
DBL2C2PF11_0521 domain (B) with age. Total/functional reactivity
is Positive if IgG or binding inhibition activity of serum against this
domain is above 0. ‘‘n’’ indicate actual numbers of hospitalized
children (A) and children with Positive reactivity (B) in the cohort.
(PPT)
Figure S5 Analysis of potential confounding factors for groups of
children with Positive (IgG.0o rB I .0) and No reactivity against
DBL2C2PF11_0521 domain at week 76 of age. Red lines indicate
medians. P values calculated using Mann-Whitney test.
(PPT)
Figure S6 Number of children with subsequent severe or
moderately severe malaria, stratified by positive and no plasma IgG
reactivity against 3 most reactive constructs measured at 76 weeks of
age, and P values against all constructs obtained in similar analyses.
(DOC)
Figure S7 Reactivity of anti-human IgG with human IgG and
human IgM. PBST, Phosphate-buffered saline buffer containing
0.05% Tween-20 (negative control). The preparation of anti-
human IgG does not recognize human IgM.
(PPT)
Table S1 Construct composition and corresponding PCR
primers for 26 PfEMP1 constructs encompassing 39 DBL and
CIDR domains. Amino acid residue numbers are shown according
to PlasmoDB database.
(XLS)
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